The U.S. Centers for Disease Control and Prevention (CDC) has reported a significant shift in the epidemiology of Clade I mpox in the United States, with more than 60 laboratory-confirmed cases across at least 20 states. In its September 25 update, the CDC noted that since August, an increasing proportion of cases have occurred among individuals with no recent international travel or known links to travelers. Domestic transmission has now been presumed in more than 10 jurisdictions, leading the CDC to state that these findings indicate a “likely transition to sustained Clade Ib transmission in the United States.” While the CDC continues to assess the risk to the general public as low, it expects additional travel-related and domestically acquired cases.
This development marks a notable change from earlier surveillance. As recently as August, the CDC reported that sustained Clade Ib transmission had not been detected in the U.S. during 2024–2025. The new assessment suggests that the virus is now spreading within the country, beyond its historical association with international travel. This shift is particularly important because the 2022 global mpox outbreak was caused by Clade IIb, while Clade I has historically been linked to more severe disease and higher mortality. However, recent Clade Ib cases in high-income countries have generally been mild, highlighting the need to distinguish between changing transmission dynamics and the immediate risk to the general population.
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines against infectious diseases and therapies for solid tumor cancers, highlighted the CDC’s update and emphasized the importance of preparedness. David Dodd, Chairman and CEO of GeoVax, commented, “CDC’s latest assessment represents an important change in the epidemiology of Clade Ib mpox in the United States. While the risk to the general population remains low, presumed domestic transmission across multiple jurisdictions reinforces the importance of continued surveillance, vaccination of appropriate at-risk populations and sustained preparedness.” Dodd continued, “Preparedness should not begin when an infectious-disease threat becomes a crisis. The appropriate time to strengthen vaccine capacity, diversify sources of supply and establish scalable manufacturing infrastructure is before those capabilities are urgently needed.”
GeoVax is advancing GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine candidate for mpox and smallpox. Following guidance from the European Medicines Agency, the company is pursuing an expedited clinical development pathway, with traditional Phase 1 and Phase 2 trials not required. GeoVax expects to initiate a pivotal Phase 3 immunobridging study with 500 participants in the fourth quarter of 2026, comparing immune responses to GEO-MVA with those of the licensed MVA-BN comparator. Results are anticipated in mid-2027. The company believes GEO-MVA could become a strategic preparedness asset by diversifying vaccine supply and enhancing manufacturing resilience. For more information, visit www.geovax.com.
The CDC’s assessment and GeoVax’s efforts underscore a broader need for proactive public health measures. As mpox transmission evolves, continued surveillance, vaccine development, and supply chain resilience will be critical to mitigating future outbreaks. The news was originally distributed by NEWMEDIAWIRE.
